SPA
NTLA icon

Sherbrooke Park Advisers’s Intellia Therapeutics NTLA Stock Holding History

Sherbrooke Park Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,898
Closed -$361K – 432
2025
Q3 		$361K Buy
20,898
+2,608
+14% +$32.1K 0.17% 244
2025
Q2 		$172K Buy
18,290
+894
+5% +$7.34K 0.07% 415
2025
Q1 		$124K Sell
17,396
-5,119
-23% -$51.7K 0.06% 489
2024
Q4 		$263K Buy
+22,515
New +$351K 0.08% 464

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sherbrooke Park Advisers's NTLA Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 20,898 shares — an estimated $361K sold.

Sherbrooke Park Advisers first reported a position in NTLA in Q4 2024 and held it in 4 quarters. The position peaked at $361K in Q3 2025. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 20,898 Intellia Therapeutics shares in Q4 2025, an estimated $361K.
  • Sherbrooke Park Advisers first reported a position in Intellia Therapeutics in Q4 2024 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Intellia Therapeutics position peaked at $361K in Q3 2025.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.